Literature DB >> 15689799

The role of vascular endothelial growth factor in ocular health and disease.

Anthony P Adamis1, David T Shima.   

Abstract

The leading causes of blindness are retinal and choroidal diseases manifesting abnormal vessel permeability and growth. Scientists have sought to understand the mechanisms underlying these pathologic conditions with the hope of developing directed and effective pharmacologic therapies. Research has yielded important new mechanistic data, making possible the development of new drugs. One of the most important targets to have emerged is a secreted protein named vascular endothelial growth factor. This review will summarize the current state of our knowledge regarding this growth factor and outline some important questions that remain to be answered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15689799     DOI: 10.1097/00006982-200502000-00001

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  82 in total

1.  Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Ratimir Lazic; Nikica Gabric
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

2.  Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).

Authors:  Lihteh Wu; María A Martínez-Castellanos; Hugo Quiroz-Mercado; J Fernando Arevalo; María H Berrocal; Michel E Farah; Mauricio Maia; José A Roca; Francisco J Rodriguez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

3.  Long-term visual and retinopathy outcomes in a predominately type 2 diabetic patient population undergoing early vitrectomy and endolaser for severe vitreous haemorrhage.

Authors:  G Ratnarajan; F Mellington; M Saldanha; S R de Silva; L Benjamin
Journal:  Eye (Lond)       Date:  2011-04-15       Impact factor: 3.775

4.  Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.

Authors:  M S Spitzer; B Wallenfels-Thilo; A Sierra; E Yoeruek; S Peters; S Henke-Fahle; K U Bartz-Schmidt; P Szurman
Journal:  Br J Ophthalmol       Date:  2006-05-24       Impact factor: 4.638

5.  Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.

Authors:  Nobuo Jo; Carolina Mailhos; Meihua Ju; Eunice Cheung; John Bradley; Kazuaki Nishijima; Gregory S Robinson; Anthony P Adamis; David T Shima
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

6.  Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes.

Authors:  David T Goldenberg; Frank J Giblin; Mei Cheng; Shravan K Chintala; Michael T Trese; Kimberly A Drenser; Alan J Ruby
Journal:  Retina       Date:  2011-02       Impact factor: 4.256

7.  One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups.

Authors:  Seungbum Kang; Young-Jung Roh
Journal:  Jpn J Ophthalmol       Date:  2009-09-08       Impact factor: 2.447

8.  Effect of anti-VEGF antibody on retinal ganglion cells in rats.

Authors:  Aya Iriyama; Yi-Ning Chen; Yasuhiro Tamaki; Yasuo Yanagi
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

9.  Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress.

Authors:  Michael I Dorrell; Edith Aguilar; Ruth Jacobson; Oscar Yanes; Ray Gariano; John Heckenlively; Eyal Banin; G Anthony Ramirez; Mehdi Gasmi; Alan Bird; Gary Siuzdak; Martin Friedlander
Journal:  J Clin Invest       Date:  2009-02-02       Impact factor: 14.808

10.  Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome.

Authors:  Lihteh Wu; Teodoro Evans; Mario Saravia; Ariel Schlaen; Cristobal Couto
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.